Spasticity / Movement Disorders
Richard Zorowitz, MD
Professor of Clinical Rehabilitation Medicine
MedStar National Rehabilitation Network and Georgetown University School of Medicine
Washington, District of Columbia, United States
Laura Serrano Barrenechea, MD
Medical Doctor
Southern Älvsborg Hospital
Borås, Vastra Gotaland, Sweden
Simon Butet, MD
Praticien Hospitalier
CHU Pontchaillou
Rennes, Bretagne, France
David Hernández Herrero, MD
Head of the Physical Medicine and Rehabilitation Service
La Paz University Hospital
Madrid, Madrid, Spain
Rama Prasad, MD
Consultant
Leicester General Hospital
Leicester, England, United Kingdom
Pascal Lecomte, n/a
Patient Author
Stroke & Go
Houyet, Namur, Belgium
Sophie Vandenbremt, n/a
Patient Caregiver Author
Stroke & Go
Houyet, Namur, Belgium
Simon Page, PhD
Global Medical Affairs Director, Neuroscience
Ipsen
London, England, United Kingdom
Mathieu Beneteau, MSc
Senior Statistician
Ipsen
Paris, Ile-de-France, France
Pascal Maisonobe, MSc
Director Biometry
Ipsen
Paris, Ile-de-France, France
Alessandro Picelli, PhD
Associate Professor
University of Verona
Verona, Veneto, Italy
Simon Page, PhD
Ipsen
London, England, United Kingdom
Eligible participants are stroke survivors (18-85y) with paresis ≤2 weeks of a first-ever stroke that has occurred within ≤4 weeks. Participants complete the PSMQ at intervals up to 12-months post stroke. Participants with a PSMQ score ≥2 undergo an in-clinic confirmatory assessment; those without clinically-confirmed PSS resume remote monitoring. All enrolled participants underwent an in-clinic confirmation visit, regardless of remote PSMQ scoring. Receiver operating characteristic (ROC) curve analyses evaluated which PSMQ items were most predictive of spasticity.
Results:
Of 372 enrolled participants, 151 were included in the interim analysis. Overall, 99 participants (65.6%) have had a PSMQ score ≥2 and 69 (45.7%) had a MAS score >0. The sensitivity of the PSMQ was 81% but the specificity was 48%. ROC analyses identified that simplifying the PMSQ to just Q1 and Q2 of the PSMQ retained the predictiveness of the tool (ROC AUC of 0.69 with items 1+2 vs 0.66 with PSMQ-total score) while reducing burden of questionnaire completion.
Conclusions: Within 1 year of their stroke, 45.7% of stroke survivors with paresis developed spasticity. Results indicate the PSMQ’s usefulness for remote monitoring of PSS development, although the threshold of ≥2 may be too sensitive, leading to high false-positive rates. The study protocol has been simplified to use solely PMSQ items 1 and 2 (rating stiffness/tightness and difficulty bending/flexing the limb) for remote monitoring. Future analyses will examine the rates, timing and severity of ‘problematic’ spasticity, and the optimal timing of remote monitoring.